New York, USA - March 30, 2026 - CD BioSciences, a leading preclinical research service provider specializing in anti-aging drug development, today reaffirms its commitment to advancing the global anti-aging research landscape by offering one-stop anti-aging drug development services that span the entire drug discovery and preclinical development pipeline. CD BioSciences' integrated solutions are designed to support pharmaceutical enterprises, research institutions, and academic investigators in translating innovative anti-aging research into viable therapeutic candidates, with a robust focus on rigorous preclinical evaluation including senolytic efficacy testing.

CD BioSciences has built a comprehensive service ecosystem for anti-aging drug discovery, covering customized solutions for diverse drug targets and drug types. Its expertise extends to targeting key molecular pathways associated with aging, such as AMPK, mTOR, SIRT1, NF-κB, and p53, while supporting the development of major anti-aging drug categories including senolytics, senomorphics, calorie restriction mimetics, and telomerase activators. A core component of CD BioSciences' anti-aging drug development services is senolytic efficacy testing, which leverages state-of-the-art in vitro and in vivo models to accurately evaluate the ability of senolytic compounds to eliminate senescent cells— a critical driver of aging and age-related diseases— and validate their therapeutic potential at the preclinical stage.

To underpin reliable and actionable preclinical data, CD BioSciences also offers a full spectrum of custom model customization services. Its model portfolio includes cellular senescence models, cross-species aging models (yeast, zebrafish, mice, rats, non-human primates), longevity models (long-lived yeast strains, Drosophila, naked mole-rat models), and aging-related disease models (neurodegenerative, cardiovascular, bone loss, sarcopenia models). Additionally, CD BioSciences provides organ-specific aging models for the skin, heart, liver, lung, kidney, and muscle, enabling clients to uncover aging mechanisms, validate therapeutic targets, and conduct senolytics efficacy testing in biological systems that closely mimic human aging processes.

CD BioSciences' preclinical development services further strengthen its anti-aging drug development services, encompassing a complete set of pharmacology, pharmacokinetics, and safety evaluation solutions. This includes in vitro ADME studies for early pharmacokinetic characterization, in vivo pharmacokinetic services to analyze bioavailability and tissue distribution, and multi-dimensional toxicity testing (in vitro dermal/ocular toxicity, non-GLP acute/chronic toxicity, genetic toxicology). Safety pharmacology services are also available to assess potential impacts of anti-aging drugs on the cardiovascular, respiratory, and central nervous systems, ensuring that drug candidates meet rigorous preclinical safety standards before advancing to further development.

With a cutting-edge lab environment and a team of experienced researchers, CD BioSciences continues to position itself as a trusted partner for the global anti-aging research community. Its focus on scientific rigor and customer-centric customization ensures that its anti-aging drug development services deliver high-quality, reliable preclinical data to fuel the next generation of anti-aging therapeutics.

About CD BioSciences

CD BioSciences is a preclinical research service provider focused on anti-aging drug development, offering one-stop solutions spanning drug discovery, pharmacology, pharmacokinetics, and safety evaluation. CD BioSciences leverages advanced platforms and extensive expertise in aging mechanism research, custom model development, and therapeutic evaluation to support pharmaceutical companies, research institutes, and academic investigators in advancing innovative anti-aging drug pipelines.

Media Contact
Company Name: CD BioSciences
Contact Person: Kikiwi Davis
Email: Send Email
Phone: 1-315-636-4280
Country: United States
Website: https://www.agingclocks.com/drug-development